表位
嵌合抗原受体
医学
癌症研究
抗原
髓系白血病
免疫学
免疫疗法
髓样
白血病
免疫系统
抗体
靶向治疗
细胞因子
生物
体内
受体
T细胞
细胞疗法
离体
叶酸受体
造血
肿瘤抗原
作者
Meng Lv,Hongli Zheng,裵緖英,Lei Lei,Wenbo Chen,Yutong Bao,Y P Ding,Zhengli Xu,L X Hu,Zhe Wan,Xueqiang Zhao,Zhixiao Zhou,Xin Lin,Xiao‐Jun Huang,Jiasheng Wang,Xiangyu Zhao
标识
DOI:10.1038/s41392-026-02765-7
摘要
Acute myeloid leukemia (AML) is a rapidly progressive malignancy with poor prognosis. To date, chimeric antigen receptor (CAR) T-cell therapy in AML has been limited by the lack of antigens with high specificity for AML cells. Here, we developed a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting LILRB4, an immunosuppressive receptor highly expressed on monocytic AML blasts but not on hematopoietic stem cells. Two nanobodies with the highest affinity for LILRB4 were identified through phage display library screening and used to construct nanobody-based dual epitope anti-LILRB4 STAR-T cells, which exhibit more potent tumor inhibition in vitro and in vivo than single epitope anti-LILRB4 STAR-T cells or dual epitope anti-LILRB4 CAR-T cells do. We subsequently conducted the first human clinical trial (NCT05548088) involving 9 patients with LILRB4-positive relapsed and refractory (R/R) AML. Six patients completed the safety and efficacy evaluation (median follow-up, 10.7 months). No immune effector cell-associated neurotoxicity (ICANS) or grade ≥3 cytokine release syndrome (CRS) was observed. Three patients died due to laboratory-confirmed infections. The best overall response rate (ORR) was 50.0% (3/6) in the efficacy assessable set and 33.3% in the full analysis set. The number of LILRB4-positive STAR-T cells significantly increased, and the number of LILRB4-positive target cells decreased. Single-cell RNA sequencing revealed that monocyte-mediated suppression of autologous T-cell function may be a primary mechanism underlying the failure of STAR-T therapy in nonresponders. In conclusion, this first-in-human trial demonstrates the therapeutic potential of targeting LILRB4 with STAR-T-cell therapy in AML and warrants further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI